Sign In
Buy RIGL
$30.30
+0.280 (+0.93%)
At Close: Jun 03, 2026
Eli Lilly Partner And Cancer Treatment Maker Nears Buy Point
01:35pm, Monday, 17'th Nov 2025
This cancer treatment stock is nearing a buy point of a base after quarterly earnings. The Eli Lilly partner reports positive trial news.
Olutasidenib continued to demonstrate durable efficacy and a manageable safety profile in a broad range of patients with R/R mIDH1 AML, including those previously treated with venetoclax-based regimen
Rigel to Present at the Jefferies Global Healthcare Conference in London
08:05am, Wednesday, 12'th Nov 2025
SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today ann
Surging Earnings Estimates Signal Upside for Rigel (RIGL) Stock
01:20pm, Thursday, 06'th Nov 2025
Rigel Pharmaceuticals (RIGL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
All You Need to Know About Rigel (RIGL) Rating Upgrade to Strong Buy
01:01pm, Thursday, 06'th Nov 2025
Rigel (RIGL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript
08:06pm, Tuesday, 04'th Nov 2025
Rigel Pharmaceuticals, Inc. ( RIGL ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Raymond Furey - Executive VP, Chief Compliance Officer, General Counsel & Corporate Secreta
Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates
06:26pm, Tuesday, 04'th Nov 2025
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.7 per share a year ago.
Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update
04:01pm, Tuesday, 04'th Nov 2025
Third quarter 2025 total revenue of approximately $69.5 million, including record net product sales of $64.1 million and contract revenues from collaborations of $5.4 million Generated $27.9 million
Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition
09:05am, Monday, 03'rd Nov 2025
Oral presentation to feature updated data from the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4 inhibitor, in patients with relapsed or refractory lower-risk MDS Four poster presentat
Rigel Gears Up to Report Q3 Earnings: Here's What to Expect
03:21pm, Friday, 31'st Oct 2025
RIGL's rising Tavalisse sales, along with incremental sales from Rezlidhia and Gavreto, could power another earnings beat in the quarter to be reported.
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is 'growing substantially'
02:20pm, Thursday, 30'th Oct 2025
Rigel Pharmaceuticals has landed on CNBC's list of top performing stocks of companies located in San Francisco.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Recommendation of “Hold” from Analysts
01:52am, Thursday, 30'th Oct 2025
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL - Get Free Report) has been given a consensus rating of "Hold" by the seven research firms that are covering the company, Marketbeat reports. Five research an
Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update
08:05am, Wednesday, 29'th Oct 2025
SOUTH SAN FRANCISCO, Calif. , Oct. 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2025 financial results after market close
Are Investors Undervaluing Rigel Pharmaceuticals (RIGL) Right Now?
10:41am, Wednesday, 15'th Oct 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Rigel (RIGL)
10:36am, Tuesday, 14'th Oct 2025
Rigel (RIGL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates cou
